Jyong Biotech Ltd.

Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, established in 2002, dedicated to the research, development, and commercialization of innovative and differentiated plant-derived drugs. The company's core mission is to address unmet medical needs, primarily focusing on urinary system diseases, with strategic market interests in the United States, the European Union, and Asia, including Taiwan and mainland China.

The company's pipeline features several key drug candidates. These include MCS-2 (also referred to as Botreso), developed for the treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS), PCP for prostate cancer prevention, and IC for interstitial cystitis/bladder pain syndrome. MCS-2 utilizes patented carotenoid chylomicron technology to enhance bioavailability.

Jyong Biotech Ltd. is led by CEO and Chairwoman Fu-Feng Kuo, who founded the company. The company became publicly traded, listing on the Nasdaq Global Market under the ticker symbol MENS in June 2025. Recent activities include the CEO outlining the company's FDA pathway and global strategy in May 2026, the filing of its annual report for fiscal year 2025, and the expansion of regional partnerships, such as a Memorandum of Understanding signed in December 2025 with a Vietnamese pharmaceutical distributor for MCS-2 market entry. The company has resubmitted a New Drug Application (NDA) for MCS-2 to the U.S. FDA in December 2021, following Phase III clinical trials, while PCP is currently in Phase II trials in Taiwan.